Document:

Third amendment to lease, dated December 24, 2009

 Exhibit 10.1 
 THIRD AMENDMENT TO LEASE 
 THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”), is made effective as of the 24th
 day of December, 2009 (the “Third Amendment Effective Date”), by and between LIBERTY PROPERTY LIMITED PARTNERSHIP, a Pennsylvania limited partnership (“Landlord”),
and ELECTRONIC ARTS-TIBURON, a Florida corporation f/k/a Tiburon Entertainment, Inc. (“Tenant”). 
 BACKGROUND: 
 A. Landlord’s predecessor in interest, ASP WT, L.L.C., a Delaware limited liability
company, and Tenant entered into that certain Lease for Space at Summit Park I, dated June 15, 2004 (the “Original Premises Lease”), with a Lease Commencement Date of January 1, 2005, and an expiration date of June 30, 2010,
for 117,201 square feet in the building known as Maitland Summit Park I, located at 1950 Summit Park Drive, Maitland, Florida (the “Original Premises”). 
 B. Landlord and Tenant entered into that certain First Amendment to Lease, dated December 13, 2005 (the “First Amendment”) for Building I and 23,163 square feet on the 6th Floor in the
building known as Maitland Summit Park II, located at 1958 Summit Park Drive, Maitland, Florida (the “Expansion Premises”) (the Original Premises and the Expansion Premises are hereafter collectively the “Leased Premises”).

 C. Landlord and Tenant entered into that certain Second Amendment to Lease, dated May 8, 2009 (the “Second
Amendment”)(with the Original Premises Lease, the First Amendment and the Second Amendment being together referred to as the “Original Lease”, and with the Original Lease, as modified by the terms and conditions of this Third
Amendment, being hereafter collectively referred to as the “Lease”) to, among other modifications, (i) extend the Lease Term for an additional period of five (5) years and four (4) months with respect to the Original
Premises and for an additional period of five (5) years with respect to the Expansion Premises, (ii) provide for two (2) additional options to renew, each for a period of five (5) years, and (iii) provide Tenant with the
option to lease the 11,039 square foot suite currently occupied by ZOM, Inc., a Florida corporation (“ZOM”), located in Building I (the “Second Expansion Premises”), to be effective no earlier than December 1, 2010 and no
later than November 30, 2013, all as more particularly set forth in the Second Amendment. 
 D. Landlord and Tenant desire
to amend the Lease to modify the Leased Premises to remove the Expansion Premises and to provide for certain other matters, contingent on Landlord’s further negotiations with ZOM and Schwab, all as set forth in this Third Amendment. 

 NOW, THEREFORE, the parties hereto, in consideration of the mutual promises and
covenants contained herein and in the Lease, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, agree as follows: 
 1. Recitals; Capitalized Terms. The recitals set forth above are true and correct and are incorporated herein by this reference. All capitalized terms not otherwise defined herein shall have the
meanings ascribed thereto in the Original Lease. 
 2. Certain Definitions. The definitions set forth in Sections 1.1 a,
e and j of the Original Lease are hereby deleted in their entirety and the following new Sections 1.1 a, e and j are inserted in place and in lieu thereof: 
 1.1 DEFINITIONS. 
  

	 	a.	Leased Premises shall mean those suites/floors within the Original Premises and, until the Expansion Premises Termination Date, the Expansion Premises, and shall
include the Second Expansion Premises if and when the option for the Second Expansion Premises is exercised by Tenant, subject to such other adjustments as are specifically contemplated and provided in the Lease. 

 * * * 
  

	 	e.	Building shall mean both Building I and Building II until the Expansion Premises Termination Date; thereafter it shall mean only Building I.

 * * * 
  

	 	j.	Tenant’s Building II Square Footage shall mean 23,163 rentable square feet until the Expansion Premises Termination Date, and thereafter it shall be zero;
Total Building II Square Footage of Building II shall mean 128,934 rentable square feet. 

 3. Change of
Leased Premises. 
 (a) Surrender of Expansion Premises. Pursuant and subject to the terms and conditions set forth
below, Landlord and Tenant have agreed to terminate this Lease with respect to the Expansion Premises effective as of May 31, 2010 (the “Expansion Premises Termination Date”). Tenant shall vacate and surrender the Expansion Premises
to Landlord on or before the Expansion Premises Termination Date in its current, “as is” condition as existing on the Third Amendment Effective Date, ordinary wear and tear or damage from casualty excepted and except for furnishings, trade
fixtures and other personal property of the Tenant (but subject to Tenant’s obligations to maintain and repair the same up to the Expansion Premises Termination Date in accordance with the Lease). Until the Expansion Premises Termination Date,
all terms, provisions, conditions and Tenant obligations and responsibilities with respect to the Expansion Premises, including, without limitation, the obligation to pay Building II Base Rent, shall continue and be in full force and effect in
accordance with the Lease. 
  

 2 

 (b) Relocation Credit. Landlord has agreed to waive any early termination fee on
account of the termination of this Lease with respect to the Expansion Premises as set forth herein and the termination fee with respect to the Expansion Premises described in Section 12.3 of the Original Lease shall not apply in connection
herewith. Further, to assist Tenant in defraying the cost of relocation, upon Tenant’s receipt of the Contingency Notice described in Section 6 below, Landlord thereafter shall provide a credit to Tenant in the amount of $600,000.00 (the
“Relocation Credit”) that shall be provided as additional Tenant Improvement Allowance. 
 (c) Effect of
Surrender. Upon the Expansion Premises Termination Date, the Leased Premises shall no longer include the Expansion Premises, and Tenant shall no longer be responsible for paying any Building II Base Rent, operating expenses or other payments due
under the Lease attributable or allocable to the Expansion Premises accruing on and after the Expansion Premises Termination Date. 
 (d) Parking. Upon the Expansion Premises Termination Date, the Authorized Number of Parking Spaces allocated to Tenant shall be reduced by 99 unreserved and 4 reserved spaces in the Building II parking structure. 
 4. Second Expansion Option. Landlord and Tenant acknowledge and agree that Tenant has exercised its Option to Lease the Second
Expansion Premises in accordance with Section 5 of the Second Amendment, but as amended pursuant to the terms of this Third Amendment and subject to the contingencies described in Section 6 below, and that Landlord has agreed that the
Tenant’s lease of the Second Expansion Premises shall commence earlier than December 1, 2010, subject to the fulfillment of the contingencies set forth herein. Accordingly, the Lease Term for the Second Expansion Premises shall commence on
June 1, 2010 (the “Second Expansion Premises Commencement Date”), and shall expire on the Lease Expiration Date. The initial base rent for the Second Expansion Premises shall be an amount equal (on a per square foot basis) to the
Building I Base Rent set forth in the Second Amendment applicable and in effect as of the Second Expansion Premises Commencement Date, and such Second Expansion Premises base rent shall be adjusted thereafter in amounts equal (on a per square foot
basis) to the Building I Base Rent adjustments set forth in Section 7 of the Second Amendment for the remaining time period of the Lease Term. 
 Notwithstanding that the Second Expansion Premises Commencement Date shall be June 1, 2010, Landlord shall use good faith efforts to provide Tenant with physical access to the Second Expansion
Premises on March 17, 2010 for the purposes of performing its Tenant Expansion Work. Further, commencing no later than February 3, 2010, Tenant shall have reasonable access to the Second Expansion Premises for the purposes of space
planning and preparing the Plans and Specifications for the Second Expansion Premises. Notwithstanding the foregoing, Landlord expects to be able to provide access to the Second Expansion Premises to Tenant to allow Tenant to commence its space
planning on an earlier date, and Tenant agrees, given the time period needed to complete all the planning, design and permitting work for the Second Expansion Premises, to commence space planning as soon as practical after Landlord provides such
access, and use good faith diligent efforts to finish Tenant’s proposed space plan as soon as practicable. For the purposes of Landlord’s review and approval of the Plans and Specifications for the Second Expansion Premises pursuant to
Section 9.B of the Second Amendment, Tenant shall deliver to Landlord its proposed space plan for the Second Expansion Premises as soon as they are completed to Tenant’s satisfaction, but no later than March 1, 2010. For the purposes
hereof, the term “Second Expansion Premises” shall mean and be defined as all rentable space located on the Third Floor of Building I not currently leased by Tenant, including without limitation the space currently leased by ZOM on the
Third Floor and the portions of the Third Floor currently used and operated as restrooms and corridors. Landlord and Tenant acknowledge and confirm that the Tenant Improvement Allowance applicable to the Second Expansion Premises, provided in
Section 9B of the Second Amendment, still applies and is in addition to the Relocation Credit described in Section 3(b) above. 
  

 3 

 Landlord acknowledges and agrees that Tenant will need to take physical possession of and
have access to the Second Expansion Premises by March 17, 2010 in order to complete the Tenant Expansion Work in time for the June 1, 2010 Second Expansion Premises Commencement Date. In the event Landlord does not deliver possession of
and physical access to the Second Expansion Premises to Tenant by March 17, 2010 due to factors that are not due to delays caused by Tenant, then for every day after March 17, 2010 until the date the Second Expansion Premises are delivered
to Tenant as contemplated herein, the Second Expansion Premises Commencement Date shall be likewise extended, on a day-for-day basis. Provided, however, in the event Landlord does not deliver possession of and access to the Second Expansion Premises
to Tenant by May 1, 2010, then: (i) Tenant shall be entitled to terminate its Option to Lease with respect to, and its lease of, the Second Expansion Premises by providing written notice thereof to Landlord no later than May 5, 2010
(whereupon Tenant’s lease and occupancy of the Second Expansion Premises shall be terminated and of no further force and effect whatsoever); and (ii) Tenant’s surrender of the Expansion Premises as provided in Section 3 above
shall be terminated and of no further force and effect whatsoever, such that the Lease will continue in full force and effect with respect to (and Tenant shall continue to lease, occupy and use) the Expansion Premises. As long as Landlord delivers
possession of and access to the Second Expansion Premises to Tenant by May 1, 2010, then nothing herein shall relieve Tenant of Tenant’s obligation to surrender possession of the Expansion Premises to Landlord on June 1, 2009 as
provided in this Third Amendment. In the event Tenant terminates its Option to Lease as provided above, this Third Amendment shall be deemed null and void and of no further force and effect whatsoever. Further, in the event Tenant terminates its
Option to Lease as provided above, Landlord shall be obligated to pay to and reimburse Tenant all of Tenant’s reasonable out-of-pocket expenses incurred in connection with the space planning and legal fees related to this Third Amendment and
its potential lease of the Second Expansion Premises in accordance with the terms and conditions of this Third Amendment, up to an amount of $100,000.00, which expenses shall be paid to Tenant no later than thirty (30) days after Tenant’s
demand therefor. Landlord hereby represents and warrants to the Tenant that no other tenant, person or entity, including without limitation Schwab, has any right of first refusal, right of first offer, option to lease, or any other right or option
to lease the Second Expansion Premises, except for the rights of Schwab that will be terminated and/or waived pursuant to the Schwab Lease Amendment described in Section 6(a) below. 
  

 4 

 5. Tenant Improvements. In Section 9A of the Second Amendment, Landlord agreed,
among other things, to provide the Tenant Refurbishment Allowance to Tenant to refurbish the existing space in the Original Premises and the Expansion Premises. The Landlord and Tenant agree that the amount of the Tenant Refurbishment Allowance is
hereby revised to be $1,427,509.00. 
 6. Contingencies. Landlord and Tenant acknowledge and agree that this Third
Amendment is intended to operate and be in full force and effect only upon the Landlord’s successful negotiations with ZOM and Schwab to allow and accommodate the terms and conditions of this Third Amendment. Accordingly, this Third Amendment
and the rights and obligations of Landlord and Tenant hereunder, are specifically subject to and conditioned upon both (i) the events described in subparagraphs 6(a) and 6(b) below occurring on or before February 26, 2010, and
(ii) Landlord notifying Tenant in writing, no later than March 3, 2010, that the events described in subparagraphs 6(a) and 6(b) below have occurred (with such written notification being referred to herein as the “Contingency
Notice”): 
 (a) Schwab Lease Amendment. Landlord and Schwab execute a lease amendment or a new lease that provides,
among other things, that Schwab waives its rights with respect to the Second Expansion Premises and agrees to lease the Expansion Premises, and otherwise in a form and content acceptable to Landlord (the “Schwab Lease Amendment”).

 (b) ZOM Lease Amendment. Landlord and ZOM, or an affiliate of ZOM, execute a lease amendment, a lease termination or a
new lease that provides, among other things, that ZOM will vacate the Second Expansion Premises on or prior to March 16, 2010, and otherwise is in a form and content acceptable to Landlord (the “ZOM Lease Amendment”). 
 Landlord’s decision to enter into the Schwab Lease Amendment and/or the ZOM Lease Amendment shall be determined in Landlord’s sole and absolute
discretion, and Landlord shall be entitled to cease negotiations of such amendments at any time. In the event that either (x) both the Schwab Lease Amendment and the ZOM Lease Amendment have not be fully executed by all the parties thereto by
February 26, 2010, or (y) Landlord has not delivered the Contingency Notice to Tenant by March 3, 2010, then this Third Amendment shall automatically become void and will not be given effect, and the Original Lease, without amendment
as set forth in this Third Amendment, shall continue in full force in accordance with its terms. In addition, in the event this Third Amendment terminates upon the failure of the foregoing contingencies, Landlord shall be obligated to pay to and
reimburse Tenant all of Tenant’s reasonable out-of-pocket expenses incurred in connection with the space planning and legal fees related to this Third Amendment and its potential lease of the Second Expansion Premises in accordance with the
terms and conditions of this Third Amendment, up to an amount of $100,000.00, which expenses shall be paid to Tenant no later than June 1, 2010 (and the foregoing obligation of Landlord to pay and reimburse Tenant such out-of-pocket expenses
shall survive any termination of this Third Amendment). 
  

 5 

 7. Surrender of Leased Premises. The first sentence of Section 12.1 of the Lease
is hereby deleted in its entirety, and the following new sentence shall be inserted in place and in lieu thereof: “On expiration of this Lease, if no Event of Default exists and subject to the Tenant’s obligations to maintain and repair
the Leased Premises in accordance with this Lease, Tenant shall surrender the Leased Premises in its current “as is” condition, ordinary wear and tear or damage from casualty excepted.” 
 8. Brokerage Commissions. Tenant and Landlord each represents to the other that no broker or agent was instrumental in procuring or
negotiating or consummating this Third Amendment, and Tenant and Landlord each agree to defend, indemnify and hold harmless the other party against any loss, cost, expense or liability for any compensation, commission, fee or charge, including
reasonable attorney’s fees, resulting from any claim of any other broker, agent or finder claiming under or through the indemnifying party in connection with this Third Amendment or its negotiation. 
 9. Reaffirmation of Guaranty. Landlord has required Tenant to obtain for Landlord’s benefit an unconditional guaranty of
Tenant’s performance of its obligations pursuant to the Lease, by Tenant’s parent company, Electronic Arts, Inc. (“Guarantor”). Guarantor executed and delivered to Landlord a certain Guaranty at the time of Tenant’s
execution of the Original Lease. As a condition to and as additional consideration for Landlord entering into this Third Amendment, Guarantor shall provide the Reaffirmation of Guaranty set forth on Exhibit “A” attached
hereto and incorporated herein by this reference, upon execution of this Third Amendment by Tenant. 
 10. Effect of
Amendment; Conflict. Except as otherwise expressly modified or amended by this Third Amendment, the Lease remains in full force and effect in accordance with its terms. In the event of a conflict between the terms and provisions of this Third
Amendment and the Lease, the terms and provisions of this Third Amendment shall control and be given effect. This Third Amendment shall be binding upon and inure to the benefit of the Landlord and the Tenant and their respective successors and
assigns. 
 11. Counterparts; Facsimile Copies. This Third Amendment may be executed simultaneously in two or more
counterparts, each one of which shall be deemed an original, but all of which shall constitute one and the same instrument. To facilitate execution, the parties agree that this Third Amendment may be executed and telecopied to the other party and
that an executed telecopy shall be binding and enforceable as an original. 
 12. Effective Date. The “Third
Amendment Effective Date” shall be the date on which the last of the Landlord or the Tenant executed this Third Amendment and delivered a signed copy to the other party; provided, however, that the effectiveness of this Third Amendment is
subject to satisfaction of the contingencies set forth in Section 6 above. The Third Amendment Effective Date shall be inserted into the first paragraph of this Third Amendment. 
  

 6 

 IN WITNESS WHEREOF, Landlord and Tenant have executed this Third Amendment intending to be
bound as of the day and year first above written. 
  

							
	Witnesses:	 		 	LANDLORD:
			
		 		 	 LIBERTY PROPERTY LIMITED PARTNERSHIP,
 a Pennsylvania limited partnership

				
	 /s/ Anne K. Toal
	 		 	By:	 	LIBERTY PROPERTY TRUST,
	Signature	 		 		 	its sole general partner
	 Anne K. Toal
	 		 		 	
	Print Name	 		 	By:	 	 /s/ Robert Goldschmidt

		 		 	Name:	 	Robert Goldschmidt
		 		 	Title:	 	Senior Vice President
	 /s/ Ivy Stanton
	 		 	Date:	 	December 23, 2009
	Signature	 		 		 	
	 Ivy Stanton
	 		 		 	
	Print Name	 		 		 	
			
		 		 	TENANT:
			
		 		 	 ELECTRONIC ARTS-TIBURON,
 A FLORIDA CORPORATION

				
	 /s/ Abra Winn
	 		 	By:	 	 /s/ Steve Bené

	Signature	 		 	Name:	 	Steve Bené
	 Abra Winn
	 		 	Title:	 	Corporate Secretary
	Print Name	 		 	Date:	 	December 15, 2009
				
	  
	 		 		 	
	Signature	 		 		 	
				
	  
	 		 		 	
	Print Name	 		 		 	

  

 7 

							
	Witnesses:	 		 	LANDLORD:
			
		 		 	 LIBERTY PROPERTY LIMITED PARTNERSHIP,
 a Pennsylvania limited partnership

				
	 /s/ Todd W. Watson
	 		 	By:	 	LIBERTY PROPERTY TRUST, 
	Signature	 		 		 	its sole general partner
	 Todd W. Watson
	 		 		 	
	Print Name	 		 	By:	 	 /s/ George J. Alburger, Jr.

		 		 	Name:	 	George J. Alburger, Jr.
		 		 	Title:	 	Chief Financial Officer
	 /s/ Stephen J. Whitley
	 		 	Date:	 	  

	Signature	 		 		 	
	 Stephen J. Whitley
	 		 		 	
	Print Name	 		 		 	

  

 8 

 EXHIBIT “A” 
 TO 
 THIRD AMENDMENT TO LEASE 
 REAFFIRMATION OF GUARANTY 
 The undersigned Guarantor previously provided a certain Guaranty to Landlord in conjunction with the Original Lease, as defined in the foregoing Third Amendment. By executing this Reaffirmation of
Guaranty, the undersigned Guarantor hereby consents to the terms and conditions of the foregoing Third Amendment, and ratifies and reaffirms the terms and conditions of the Guaranty, which Guaranty shall remain in full force and effect. The
Guarantor hereby waives any defense to its obligations under the Guaranty based upon or arising out of the modifications to the Lease as provided in the First Amendment, the Second Amendment or in the foregoing Third Amendment. Notwithstanding any
language contained in the Guaranty, Guarantor, to the extent permitted by law, waives any claim or other right which such Guarantor might now have or hereafter may acquire against Tenant, which arises from the existence or performance of such
Guarantor’s liability or other obligations under the Guaranty. 
 IN WITNESS WHEREOF, the undersigned has executed the
Reaffirmation of Guaranty on the date written below intending to be bound as of the Third Amendment Effective Date. 
  

			
	GUARANTOR:
	
	ELECTRONIC ARTS, INC.
		
	By:	 	 /s/ Steve Bené

	Name:	 	Steve Bené
	Title:	 	Senior Vice President/General Counsel
	Date:	 	December 15, 2009

  

 9Consulting Agreement, effective as of January 6, 2010

 Exhibit 10.1 
 CONSULTING AGREEMENT 
 This CONSULTING
AGREEMENT (this “Agreement”) is effective as of this 6th day of January, 2010 (the “Effective Date”), by and between PHARMASSET, INC., with offices at 303-A College Road East, Princeton, NJ
08540 (“PHARMASSET”) and FREDRIC D. PRICE, of 64 Quarry Lane, Bedford, NY 10506 (“CONSULTANT”). PHARMASSET and CONSULTANT are each referred to herein as a “Party” and
collectively as the “Parties.” 
 RECITALS: 
 WHEREAS, PHARMASSET would like CONSULTANT to provide certain consulting services and CONSULTANT would like to provide such services
upon the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual
promises contained herein, the Parties hereto agree as follows: 
 1. SERVICES. 
 During the Term (as defined in Section 4 below), CONSULTANT agrees to provide the consulting services as further described on
Exhibit A attached hereto (the “Services”). 
 2. COMPENSATION. 
 As consideration for CONSULTANT’s performance of the Services, PHARMASSET shall pay CONSULTANT the amount set forth in Exhibit A
(the “Consultant Fee”). PHARMASSET shall also pay CONSULTANT for reasonable and necessary travel and other expenses approved in advance by PHARMASSET that are incurred by CONSULTANT in the performance of the Services. No
other form of compensation shall be paid by PHARMASSET to CONSULTANT except as otherwise approved in writing by PHARMASSET. PHARMASSET is required to file IRS Form 1099 with the United States Internal Revenue Service for all payees. Therefore, at
PHARMASSET’s request, CONSULTANT shall provide PHARMASSET with CONSULTANT’s Social Security or Federal Identification Number, as applicable, upon execution of this Agreement. 
 3. REPRESENTATIONS AND WARRANTIES. CONSULTANT represents, warrants and covenants to PHARMASSET that CONSULTANT: 
 (a) is not now a party to any agreement which would prevent CONSULTANT from fulfilling CONSULTANT’s obligations under this Agreement and CONSULTANT will not knowingly enter into any agreement with
any other party that would in any way prevent CONSULTANT from performing the Services; 
 (b) is not and has never been
(i) under investigation for debarment or debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a), as amended, or any similar state law or regulation, (ii) excluded by the Office of Inspector General pursuant
to 42 U.S.C. § 1320a-7, et seq. or any state agency from participation in any federal or state health care program; or (iii) otherwise disqualified or restricted by the FDA pursuant to 21 C.F.R. 312.70 or any other regulatory authority;

 (c) will notify PHARMASSET immediately in the event any investigation or proceeding for debarment, exclusion or
disqualification is initiated against CONSULTANT; 

 (d) is qualified and has sufficient technical expertise to perform the Services; and

 (e) will perform the Services in compliance in all material respects with all applicable foreign, federal, state and local
laws, rules and regulations. 
 4. TERM AND TERMINATION. 
 (a) Term. This Agreement shall begin as of the Effective Date and shall expire on March 31, 2010 (the
“Term”). Notwithstanding the foregoing, the Parties may mutually agree in writing to extend the Term. 
 (b) Termination. This Agreement may be terminated as follows: (i) immediately by either Party in the event of a material breach by the other Party, if such breach is not cured within fifteen (15) days after the
breaching Party’s receipt of written notice of such breach from the non-breaching Party; and (ii) by CONSULTANT by giving PHARMASSET fifteen (15) days prior written notice of termination. 
 (c) Effect of Termination. In the event of early termination, CONSULTANT shall immediately discontinue performing the
Services. 
 5. CONFIDENTIALITY. 
 (a) Confidential Information Defined. CONSULTANT acknowledges and agrees that any data, documents, materials or information of any type whatsoever, in whatever form or medium, whether or not
marked as “confidential” or “proprietary,” and which could reasonably be expected to be valuable or sensitive to PHARMASSET, including but not limited to, any information concerning or relating to the property, products,
research, development, technology, business and affairs of PHARMASSET, that is learned, created by, disclosed to or becomes known by CONSULTANT pursuant to this Agreement constitutes the confidential information of PHARMASSET (collectively,
“Confidential Information”). Consultant shall treat all Confidential Information as confidential and shall only use such Confidential Information to perform the Services under this Agreement. Consultant shall not use any
Confidential Information for personal gain or in connection with a purchase or sale of PHARMASSET common stock. These restrictions upon disclosure and use of Confidential Information shall continue during the Term and shall extend beyond the Term
for a period of ten (10) years. Upon expiration or termination of this Agreement, CONSULTANT will, at the request of PHARMASSET, return or destroy all written and electronic copies of any Confidential Information in CONSULTANT’s
possession. 
 (b) Exceptions to Confidential Information. Notwithstanding the foregoing, Confidential Information
shall not include information which: (i) is or hereafter becomes generally available to the trade or public other than by reason of any breach hereof; (ii) was already known to CONSULTANT, prior to the date of disclosure; (iii) is
disclosed to CONSULTANT by a third party who has the right to disclose such information without any obligations of confidentiality; or (iv) is otherwise required to be disclosed by CONSULTANT in order to comply with applicable legal
requirements of a public authority, law, rule of court or regulation, provided that (a) CONSULTANT promptly notifies PHARMASSET of the obligation to disclose in order to allow PHARMASSET to object or seek a protective order; (b) CONSULTANT
only discloses the minimum amount of Confidential Information that is necessary to comply with the required disclosure; and (c) such information remains Confidential Information for all other purposes. 
  

 2 

 6. WORK PRODUCT. 
 (a) Inventions. CONSULTANT agrees that any inventions, works of authorship, other intellectual property and/or scientific information or documentation that is conceived, developed,
originated, fixed or reduced to practice by CONSULTANT resulting from CONSULTANT’s engagement by PHARMASSET (collectively, “Inventions”), shall be the sole and complete property of PHARMASSET or any of its Affiliates,
and shall be treated as Confidential Information. CONSULTANT shall fully and promptly disclose to PHARMASSET all Inventions conceived or reduced to practice by CONSULTANT. CONSULTANT hereby assigns and conveys to PHARMASSET or any of its Affiliates
CONSULTANT’s entire right, title and interest to any and all Inventions. CONSULTANT agrees to execute all assignments, declarations, powers of attorney, applications or registrations for patents and copyrights, and any other instruments deemed
necessary or helpful for PHARMASSET or its Affiliates to secure and enforce its rights hereunder. 
 (b) Use of PHARMASSET
Materials. CONSULTANT will only use the materials provided by or on behalf of PHARMASSET under this Agreement consistent with and as contemplated by this Agreement and will not undertake any actions which would jeopardize the copyright,
trademark, tradename and other intellectual property rights of PHARMASSET or its Affiliates in any such materials. 
 7.
INDEMNIFICATION. 
 Each Party shall indemnify, defend and hold harmless (the
“Indemnitor”) the other Party and its respective affiliates, employees, officers, directors, attorneys, agents, representatives, successors and assigns (collectively, the
“Indemnitee”) from and against all causes of action, liabilities, damages, penalties, costs, expenses, fines, claims, losses, suits, demands, liens, and all expenses of any kind or nature whatsoever (including,
without limitation, reasonable attorneys’ fees) (collectively, “Losses”) that may be incurred by, made, charged, or instituted against an Indemnitee, and which arise out of, result from or are based on
(a) the material breach of this Agreement by the Indemnitor; or (b) the negligence or willful misconduct of the Indemnitor, except to the extent that such Losses are attributable to the negligence, wrongful act or omission, willful
malfeasance or misconduct by the Indemnitee. 
 8. MISCELLANEOUS. 
 (a) Entire Agreement; Modification. This Agreement together with any exhibits attached hereto constitutes the entire
understanding and agreement between the Parties with respect to the subject matter covered herein and supercedes any and all prior agreements, understandings, covenants, promises, warranties and representations, oral or written, express or implied,
between the Parties that relates to the subject matter hereof. This Agreement may not be amended or supplemented in any way except in writing, dated and signed by authorized representatives of both Parties. 
 (b) Publicity. CONSULTANT shall not disclose the fact of, terms of, or subject matter of this Agreement to any third party
without the prior written consent of PHARMASSET. CONSULTANT will not disclose any material of any kind that uses the name, logo, trademark or tradename of PHARMASSET or any Affiliate without PHARMASSET’s prior written consent. 
 (c) Independent Contractors. The Services set forth herein shall be performed by CONSULTANT as an independent contractor and
shall not create an employer/employee relationship between CONSULTANT and PHARMASSET. Consequently, CONSULTANT shall not be entitled to receive any employee benefits which are made available to employees of PHARMASSET. CONSULTANT shall not have
actual, apparent, or implied authority to bind PHARMASSET to any obligation whatsoever. 
  

 3 

 (d) Assignment. The Services provided herein are personal in nature and,
therefore, CONSULTANT may not assign or transfer this Agreement or any part hereof without the express written consent of PHARMASSET. PHARMASSET may assign its rights and obligations under this Agreement without CONSULTANT’s consent.

 (e) Notice. Any notices, consents or other communications required or permitted under this Agreement must be in
writing and shall be deemed to have been duly given as of the date (a) actually delivered by hand; (b) three (3) days after being sent by registered or certified mail, postage prepaid, return receipt requested; or (c) actually
delivered by overnight courier, to the other Party at the address as set forth below, or to such other address or addresses as may be designated in writing by notice given to the other Party pursuant to this paragraph: 
  

			
	If to CONSULTANT:	  	Fredric D. Price
		  	64 Quarry Lane
		  	Bedford, NY 10506
		
	If to PHARMASSET:	  	Pharmasset, Inc.
		  	Attention: General Counsel
		  	303-A College Road East
		  	Princeton, NJ 08540

 (f) Severability;
Waiver. The invalidity or unenforceability of any term or provision of this Agreement shall not affect the validity or enforceability of any other term or provision of this Agreement. Waiver by either Party or the failure by either Party to
claim a breach of any provision of this Agreement shall not be deemed to constitute a waiver or estoppel with respect to any subsequent breach of any provision hereof. 
 (g) Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of New Jersey, without regard to its conflict of laws rules or principles.

 (h) Survival. All provisions of this Agreement which may reasonably be interpreted or construed as surviving
termination shall survive, including without limitation Sections 5, 6, 7 and 8. 
 [Signature page follows.]

  

 4 

 IN WITNESS WHEREOF, the Parties have each caused this Agreement to be executed by
their duly authorized representatives as of the Effective Date. 
  

									
	PHARMASSET:	 		 	CONSULTANT:
			
	PHARMASSET, INC.	 		 	FREDRIC D. PRICE
				
	By:	 	/S/    PAUL
LUBETKIN        	 		 	 /S/    FREDRIC D.
PRICE        

					
	Name:	 	PAUL LUBETKIN	 		 		 	
					
	Title:	 	Executive Vice President, General Counsel, and Secretary	 		 		 	

  

 5 

 EXHIBIT A 
 SERVICES AND COMPENSATION 
  

	1.	Services. In accordance with the terms and conditions of the Agreement to which this Exhibit is attached and incorporated therein by reference, the
CONSULTANT shall perform the following Services: 

  

	 	a)	At the request of the PHARMASSET board or management, provide counsel and advice about PHARMASSET’s opportunities, business development strategies and programs, or
financial or other strategies and opportunities; and 

  

	 	b)	Other services as may be requested by PHARMASSET from time to time. 

  

	2.	Compensation. 

 In
consideration of the performance of Services as described above, PHARMASSET shall (a) allow CONSULTANT to retain the March 23, 2009 restricted stock grant awarded to him as a member of its board of directors until such grant is fully
vested and shall thereafter use reasonable efforts consistent with the federal securities laws to assist CONSULTANT in obtaining unlegended certificates, and (b) extend until December 31, 2010 CONSULTANT’s right to exercise PHARMASSET
stock options held by him which are fully vested and exercisable as of March 17, 2010.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}]]